Trial Profile
A Randomized, Placebo-controlled, Double-blind, Proof-of-concept Study of Intravenous Secukinumab (AIN457) or Canakinumab (ACZ885) in Dry Eye Syndrome
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2016
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary) ; Secukinumab (Primary)
- Indications Dry eyes
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 18 Dec 2014 New trial record